Cardioloxía
Servicio
University of Glasgow
Glasgow, Reino UnidoPublicacións en colaboración con investigadores/as de University of Glasgow (16)
2024
-
Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry
Journal of Cardiac Failure
-
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
Journal of the American Heart Association, Vol. 13, Núm. 15, pp. e035993
-
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4
Journal of Cardiac Failure
-
Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial
Circulation: Cardiovascular Interventions, Vol. 17, Núm. 6, pp. 457-473
2023
-
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology, Vol. 81, Núm. 1, pp. 34-45
2022
-
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up
European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103
-
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
The Lancet Diabetes and Endocrinology, Vol. 10, Núm. 1, pp. 35-45
-
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis
Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412
-
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis
European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058
2021
-
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
New England Journal of Medicine, Vol. 384, Núm. 2, pp. 105-116
-
Empagliflozin in heart failure with a preserved ejection fraction
New England Journal of Medicine, Vol. 385, Núm. 16, pp. 1451-1461
2020
-
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
European Journal of Heart Failure, Vol. 22, Núm. 11, pp. 2160-2171
2019
-
Effects of serelaxin in patients with acute heart failure
New England Journal of Medicine, Vol. 381, Núm. 8, pp. 716-726
2015
2013
-
Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: Analysis from the SHIFT study
Clinical Research in Cardiology, Vol. 102, Núm. 1, pp. 11-22
2008
-
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
The Lancet, Vol. 372, Núm. 9641, pp. 807-816